A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Trial Profile

A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Cobicistat/darunavir (Primary) ; Darunavir (Primary) ; Etravirine (Primary) ; Rilpivirine (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics; Registrational
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 14 Feb 2017 Status changed from recruiting to completed.
    • 03 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
    • 06 May 2016 Interim results (n=15) published in the JAIDS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top